幼年特发性关节炎患者接种麻疹-腮腺炎-风疹加强疫苗的安全性:一项长期随访研究
该回顾性研究在UMC Utrecht纳入186例接受免疫抑制和免疫调节治疗的幼年特发性关节炎(JIA)患者,收集接种麻腮风(MMR)加强疫苗前后各两次访视的临床资料,分析疫苗相关不良事件及疾病活动度变化。结果显示接种后调整疾病活动度评分与接种前无显著差异,7%患者报告轻度不良事件,无严重不良事件,结论认为MMR加强疫苗在长期随访中安全且不加重疾病活动。
要点
- 接种时51%患者使用csDMARD,28%使用bDMARD。
- 接种后调整疾病活动度评分与接种前无显著差异。
- 7%患者报告轻度不良事件,无严重不良事件。
核心结论
- 在长期随访中,MMR加强疫苗接种对接受csDMARD和生物DMARD治疗的JIA患者是安全的,且未加重疾病活动。
研究设计与样本
- 在UMC Utrecht进行的回顾性研究,纳入186例JIA患者,收集接种MMR加强疫苗前后各两次访视的临床和治疗数据。
主要发现
- 接种时51%的患者使用csDMARD,28%使用bDMARD。
- 接种后调整疾病活动度评分与接种前无显著差异。
- 7%的患者报告了与MMR加强疫苗相关的轻度不良事件,无严重不良事件报告。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To study short and long-term disease activity and vaccine-related adverse events in a cohort of JIA patients who received the live attenuated measles-mumps-rubella (MMR) booster vaccine while being treated with immunosuppressive and immunomodulatory therapies. METHODS: A retrospective study was performed in the UMC Utrecht, clinical and therapeutic data were collected from electronic medical records for two visits before and two visits after the MMR booster vaccine of JIA patients. Drug therapy was collected and adverse events related to the vaccine were requested from the patients during clinical visits or by short phone interviews. Associations between MMR booster vaccination and the active joint count, physician global assessment of disease activity, patient-reported visual analogue scale (VAS) for well-being and clinical Juvenile Arthritis Disease Activity Score (cJADAS) were analyzed using multivariable linear mixed effects analyses. RESULTS: A total of 186 JIA patients were included in the study. At the time of vaccination, 51% of the patients used csDMARD and 28% used bDMARD therapy. Overall, adjusted disease activity scores after MMR booster vaccination were not significantly different compared to pre-vaccination. Mild adverse events related to the MMR booster were reported for 7% of the patients. No serious adverse events were reported. CONCLUSION: MMR booster vaccination was safe and did not worsen disease activity during long-term follow-up in a large cohort of JIA patients being treated with both csDMARDs and biological DMARDs.
引用
- Hamad Saied M, van Straalen JW, de Roock S, et al. Safety of Measles-Mumps-Rubella booster vaccination in patients with juvenile idiopathic arthritis: A long-term follow-up study. Vaccine. 2023. PMID: 37032229. doi:10.1016/j.vaccine.2023.03.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。